Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Pathol Int ; 74(6): 317-326, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38634742

RESUMO

Immune checkpoint inhibitors (ICIs) can provide survival benefits to cancer patients; however, they sometimes result in the development of renal immune-related adverse events (irAEs). Tubulointerstitial nephritis (TIN) is the most representative pathological feature of renal irAEs. However, the clinicopathological entity and underlying pathogenesis of ICI-induced TIN are unclear. Therefore, we compared the clinical and histological features of this condition with those of non-ICI drug-induced TIN. Age and C-reactive protein levels were significantly higher in ICI-induced TIN, but there were no significant differences in renal function. Immunophenotyping of ICI-induced TIN showed massive T cell and macrophage infiltration with fewer B cells, plasma cells, neutrophils, and eosinophils. Compared with those in non-ICI drug-induced TIN, CD4+ cell numbers were significantly lower in ICI-induced TIN but CD8+ cell numbers were not significantly different. However, CD8/CD3 and CD8/CD4 ratios were higher in ICI-induced TIN. Moreover, CD25+ and FOXP3+ cells, namely regulatory T cells, were less abundant in ICI-induced TIN. In conclusion, T cell, B cell, plasma cell, neutrophil, and eosinophil numbers proved useful for differentiating ICI-induced and non-ICI drug-induced TIN. Furthermore, the predominant distribution of CD8+ cells and low accumulation of regulatory T cells might be associated with ICI-induced TIN development.


Assuntos
Linfócitos T CD8-Positivos , Inibidores de Checkpoint Imunológico , Nefrite Intersticial , Linfócitos T Reguladores , Humanos , Nefrite Intersticial/induzido quimicamente , Nefrite Intersticial/patologia , Nefrite Intersticial/imunologia , Inibidores de Checkpoint Imunológico/efeitos adversos , Masculino , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/patologia , Linfócitos T Reguladores/efeitos dos fármacos , Feminino , Idoso , Linfócitos T CD8-Positivos/patologia , Linfócitos T CD8-Positivos/imunologia , Pessoa de Meia-Idade , Adulto , Idoso de 80 Anos ou mais
2.
CEN Case Rep ; 9(2): 165-172, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-31974826

RESUMO

The immunoglobulin (Ig) D type is a rare variant of multiple myeloma (MM), that accounts for 1-2% of all cases. Compared to the more common types of MM, IgD MM is known to have more severe symptoms at presentation, and a poorer prognosis. A woman was admitted to our hospital for severe acute kidney disease and disorder (AKD) and back pain, and was started on hemodialysis. The renal biopsy revealed light chain cast nephropathy. She was diagnosed with IgD-λ MM based on Bence-Jones protein expression and high IgD serum levels, and started bortezomib therapy with plasma exchange (PE). After three sessions of PE, the serum free light chain levels decreased by 92%, and she was withdrawn from dialysis. The patient underwent autologous transplantation and is still in remission, demonstrating the benefits of a bortezomib-based regimen in combination with PE for IgD MM with AKD.


Assuntos
Bortezomib/uso terapêutico , Imunoglobulina D/sangue , Cadeias lambda de Imunoglobulina/sangue , Nefropatias/etiologia , Mieloma Múltiplo/complicações , Mieloma Múltiplo/terapia , Doença Aguda , Povo Asiático/etnologia , Proteína de Bence Jones/metabolismo , Bortezomib/administração & dosagem , Terapia Combinada , Feminino , Humanos , Cadeias lambda de Imunoglobulina/efeitos dos fármacos , Rim/efeitos dos fármacos , Rim/fisiopatologia , Nefropatias/terapia , Pessoa de Meia-Idade , Mieloma Múltiplo/metabolismo , Troca Plasmática , Inibidores de Proteassoma/administração & dosagem , Inibidores de Proteassoma/uso terapêutico , Recuperação de Função Fisiológica , Indução de Remissão , Diálise Renal , Transplante Autólogo/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA